In this section of the AAO 2015 Tradeshow Site, you'll find news releases from our exhibitors. The releases are listed in chronological order and are archived by month and year.
- Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept
- More than 350,000 TECNIS Symfony® and Symfony® Toric lenses, the first-ever extended depth of focus presbyopia correcting lenses, now in use by cataract patients worldwide
